---
title: "Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286093557.md"
description: "Xilio Therapeutics, Inc. reported Q1 2026 revenue of $12.6M, up from $2.9M YoY, with a net loss of $(9.5) M, an improvement from $(13.3) M last year. The revenue increase was driven by collaborations with AbbVie and Gilead, while R&D expenses rose by $11.6M. The company expects to fund operations into early 2028 with current cash and potential Series C warrant exercises. Clinical trials for vilastobart and efarindodekin alfa are ongoing, with a milestone achieved in Q2 2026."
datetime: "2026-05-12T11:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286093557.md)
  - [en](https://longbridge.com/en/news/286093557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286093557.md)
---

# Xilio Therapeutics, Inc. 1Q 2026: Revenue $12.6M, EPS $(0.58) — 10-Q Summary

Xilio Therapeutics, Inc. reported first-quarter 2026 results with revenue rising to $12.6M and a narrower net loss versus the year-ago quarter. Collaboration and license agreements with AbbVie and Gilead drove revenue growth while higher R&D spending weighed on results.

**Financial Highlights**

-   Revenue was $12.6M for Q1 2026, compared with $2.9M in the year-ago quarter; YoY change +$9.7M.
-   Net income: Net loss attributable to common stockholders was $(9.5) M for Q1 2026 versus a net loss of $(13.3) M in the year-ago quarter (improved $3.7M YoY).
-   Diluted EPS was $(0.58) for Q1 2026, compared with $(2.49) in the year-ago quarter (improved YoY).

**Business Highlights**

-   Revenue growth was driven by collaboration and license revenue from AbbVie and Gilead, which lifted receipts by $9.7M to $12.6M.
-   R&D spending accelerated, increasing by $11.6M, primarily to support IND-enabling manufacturing for XTX501 and expanded preclinical activities.
-   Clinical programs remain active, including ongoing Phase 1/2 and Phase 2 trials for vilastobart and efarindodekin alfa; an AbbVie milestone was achieved in Q2 2026.
-   Liquidity: cash on hand plus the expected AbbVie milestone are expected to fund operations into early 2028; the company noted potential additional liquidity of $36.2M if Series C warrants are exercised.

Original SEC Filing: Xilio Therapeutics, Inc. \[ XLO \] - 10-Q - May. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [XLO.US](https://longbridge.com/en/quote/XLO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/286893590.md)
- [Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline](https://longbridge.com/en/news/286673327.md)
- [Mubadala Investment Co Pjsc Raises Share Stake In Abbvie, Match Group,Cuts In CVS Health](https://longbridge.com/en/news/286587009.md)
- [Gilead Sciences prices $3B multi-tranche senior notes offering](https://longbridge.com/en/news/286518399.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)